Vertex's HCV Drug Might Gain Advantage Over Merck's From FDA Draft Guidance

FDA’s draft guidance on chronic hepatitis C drug development inspired one analyst to predict an advantage for Vertex Pharmaceuticals’ telaprevir over Merck & Co.’s boceprevir.